Insider buying last 90 days
No open-market insider purchases were filed for DYN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DYN insider filing, plotted on the chart in Gekko.Open DYN in Gekko
NASDAQ: DYN
Dyne Therapeutics (DYN) Stock Analysis & Forecast
Oct 12 close
$15.96−0.68 (−4.1%)
Gekko Brief
AI summaryOct 12 closeDyne Therapeutics this week drew attention mainly for fresh one-year data from its Phase 1/2 ACHIEVE trial of DYNE-101 (also referenced as zeleciment basivarsen) in myotonic dystrophy type 1, with reports describing sustained functional and strength improvements and a favorable safety profile. Commentary framed this alongside a narrative of the stock being undervalued. Separately, director Brian S. Posner purchased 2,500 shares at $16 per share on 2 October 2026, increasing his direct holdings to 27,000 shares.
DYN closed at $15.96, down 4.1% on the day, sitting below both its 50-day average of $21.40 and its 200-day average of $19.50. The one-month return stands at -12.4%, the three-month at -32.9%, the six-month at -16%, while the one-year return is 8.7%. The GekkoIndex reads 66.2, placing the stock in the Accumulation zone, down 3.5 over five days. Price sits 26.6% below Gekko Fair Value of $21.75.
Dyne's next earnings date is 4 November 2026, 23 days away, falling inside a typical 20-trading-day holding window; the prior quarter showed an EPS of -1.08 against an estimate of -0.75, with a 0.3% reaction, and five beats across eight quarters reported, with an average absolute reaction of 9.8%. Seasonality from this point in the calendar has averaged a 2.6% move over the next 20 trading days across 5 years, rising in 3 of them. Analyst coverage from 14 firms includes 13 buy ratings, 1 hold, and a consensus target of $35.73, implying 123.9% upside per that consensus.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Dyne Therapeutics price vs fair value
Close $15.96200-day averageGekko Fair Value $21.75
Dyne Therapeutics quick facts
- Market cap
- $2.98B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.30
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.12
- Volume
- 2.92M avg 3.31M
- 1-year return
- +8.7%
- Typical daily move
- ±5.1%
- Typical 20-day move
- ±14.6%
- 50-day average
- $21.40
- 200-day average
- $19.50
- Next earnings
- Nov 4
- Shares outstanding
- 186.7M
Dyne Therapeutics swing-trade checklist
Dyne Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $15.96 sits between the 50-day ($21.40) and 200-day ($19.50) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.2, Accumulation
Reading 66.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
26.6% below
Price is 26.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Dyne Therapeutics stock chart and price history
Dyne Therapeutics closed at $15.96 on Oct 12, 2026, +8.7% over the past year, inside a 52-week range of $13.73 to $27.31.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.4%
- 3 months
- −32.9%
- 6 months
- −16.0%
- 1 year
- +8.7%
The full DYN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DYN in Gekko
Follow Dyne Therapeutics through every session
Put DYN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DYN in GekkoFree for 7 days. No credit card required.
Dyne Therapeutics GekkoIndex: the smart money zone
Dyne Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.2, in the Accumulation zone, down 3.5 points over five sessions.
66.2Accumulation
Down 3.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 64 | −1.0% | +5.7% | ||
| Accumulation (current zone) | 206 | −0.9% | −3.0% | ||
| Neutral | 373 | +2.1% | +4.0% | ||
| Distribution | 37 | −3.1% | +2.8% | ||
| Selling | 2 | Too few readings yet | |||
Average DYN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the DYN price, zone by zone.Track DYN in Gekko
Is Dyne Therapeutics stock overvalued? Gekko Fair Value
Dyne Therapeutics trades 26.6% below Gekko Fair Value of $21.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Dyne Therapeutics shares are worth, recalculated every trading day.
$21.75
Gekko Fair Value, Oct 10, 2026
26.6% Undervalued
At the end of Aug 2026 the price was 9.0% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open DYN in Gekko
Dyne Therapeutics insider and Congress trading
No open-market insider purchases were filed for Dyne Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DYN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DYN, plotted on the chart in Gekko.Open DYN in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold DYN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Dyne Therapeutics earnings: next date and track record
Dyne Therapeutics reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- −$0.91
5 of 8reports beat the EPS estimate
±9.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$1.08 est −$0.75 | — | +0.3% |
| May 11, 2026 | −$0.73 est −$0.78 | — | +4.3% |
| Mar 2, 2026 | −$0.73 est −$0.77 | — | −6.5% |
| Nov 5, 2025 | −$0.76 est −$0.81 | — | −15.4% |
| Jul 28, 2025 | −$0.97 est −$0.99 | — | −7.5% |
| May 8, 2025 | −$1.05 est −$0.84 | — | +21.4% |
| Feb 27, 2025 | −$0.88 est −$0.91 | — | −1.3% |
| Nov 12, 2024 | −$0.96 est −$0.71 | — | +21.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Dyne Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Dyne Therapeutics is $35.73, +123.9% from the last close, from 14 firms rating the stock in the last 90 days.
$35.73consensus 12-month target, +123.9% from the last close
Now $15.96Avg $35.73
Low $26High $50
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 30 | H.C. Wainwright | $32 | +100.5% |
| Sep 30 | Stifel Nicolaus | $37 | +131.8% |
| Sep 30 | LifeSci Capital | $40 | +150.6% |
| Sep 29 | Piper Sandler | $47 | +194.5% |
| Sep 23 | Raymond James | $37 | +131.8% |
−3.0%average 20-day move after past Accumulation readings
+2.6%average move over the next 20 trading days in the last 5 years
±5.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Dyne Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Dyne Therapeutics averaged +2.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.1% | 3 of 5 |
| Next 10 trading days | −2.1% | 2 of 5 |
| Next 15 trading days | +4.5% | 2 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +8.4% | 3 of 5 |
For scale, DYN’s typical 20-trading-day move in either direction is about 14.6%.
Dyne Therapeutics market cap and key statistics
Dyne Therapeutics’s market cap is $2.98B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $2.98B
- EPS, TTM
- −$3.30
- Gekko Fair Value
- $21.75
Trading
- Volume
- 2.92M
- Avg volume, 20 days
- 3.31M
- 52-week high
- $27.31
- 52-week low
- $13.73
- Shares outstanding
- 186.7M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -81.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.12
- Typical daily move
- ±5.1%
- Typical 20-day move
- ±14.6%
Dyne Therapeutics stock news this week
Coverage of Dyne Therapeutics this week reads positive: 4 positive, 0 neutral and 0 negative headlines.
- How (DYN) Movements Inform Risk Allocation ModelsStock Traders Daily, Oct 11
- Dyne Therapeutics (DYN) After Fresh ACHIEVE Data With Undervalued Narrative IntactSimply Wall Street, Oct 7
- At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares.Stock Titan, Oct 6
- Does One Year DM1 Trial Data Change The Bull Case For Dyne Therapeutics Stock?Simply Wall Street, Oct 6
Dyne Therapeutics peers
Dyne Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Dyne Therapeutics stock FAQ
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $2.98B at the Oct 12, 2026 close of $15.96, with 186.7M shares outstanding.
What is the Dyne Therapeutics stock forecast?
The consensus analyst 12-month price target for Dyne Therapeutics is $35.73, +123.9% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Dyne Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Dyne Therapeutics is undervalued: the Oct 12, 2026 close of $15.96 is 26.6% below Gekko Fair Value of $21.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Dyne Therapeutics report earnings next?
Dyne Therapeutics is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of −$0.91 per share. Dyne Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 9.8% on average across the report.
What is Dyne Therapeutics’s 52-week high and low?
Dyne Therapeutics’s 52-week high is $27.31 and its 52-week low is $13.73; it closed at $15.96 on Oct 12, 2026, +8.7% over the past year. Over the last five years the shares peaked at $47.45 on Aug 20, 2024.
Is Dyne Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Dyne Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.